Austin, TX
Psychedelic Therapy clinics in Austin
Psychedelic-assisted therapy in Austin sits mostly in the ketamine-assisted psychotherapy category, with some clinics also preparing for state-specific psilocybin frameworks. Psychiatric referrals for complex cases route through Ascension Seton, St David's HealthCare, and Dell Medical School at UT Austin. Demand reflects a young, tech-heavy, health-literate population with strong cash-pay demand.
Ketamine-assisted psychotherapy has the strongest US evidence base among psychedelic modalities. Psilocybin is not FDA approved and is only legally accessible within research or specific state programs. MDMA therapy is investigational. Clinics in Austin, Texas should be evaluated for therapist training, safety protocols, and honest evidence framing. Texas Medical Board and PA/NP supervision requirements for office infusions determines what can legally be offered.
With psychedelic therapy clinics on Regenerated.com in Austin, patients can compare clinician training, integration support, and legal framework before booking.
Roots Behavioral Health - Lost Creek - A Hightop Health Clinic
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Psychedelic Therapy
Regulatory context
A note on Texas's psychedelic therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
HB 1802 / Psilocybin and MDMA Research (2021)
Required Texas Health and Human Services Commission to study psilocybin and MDMA for PTSD treatment in veterans; report completed. -
Texas Ibogaine Initiative (HB 3717, 2025 pending)
Would allocate $50 million for FDA-regulated ibogaine clinical trials, potentially the largest state psychedelic research investment in US history. -
Texas Controlled Substances Act
Mirrors federal scheduling.
Texas enforces federal scheduling. The Texas Medical Board oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. Texas PMP requires controlled substance reporting. Texas has seen rapid ketamine clinic growth in Austin, Dallas, and Houston markets with corresponding enforcement attention on compounding and telehealth practices.